Designer drugs 2015: assessment and management

Recent designer drugs, also known as “legal highs,” include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as “bath salts”); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment.

[1]  R. McLay,et al.  Psychosis associated with synthetic cannabinoid agonists: a case series. , 2011, The American journal of psychiatry.

[2]  Arshid Mir,et al.  Myocardial Infarction Associated With Use of the Synthetic Cannabinoid K2 , 2011, Pediatrics.

[3]  D. Thornley‐Brown,et al.  AKI associated with synthetic cannabinoids: a case series. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[4]  S. Schnoll,et al.  Role of the primary care physician in problems of substance abuse. , 1999, Archives of internal medicine.

[5]  Tracy L. Brewer,et al.  A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. , 2014, Journal for specialists in pediatric nursing : JSPN.

[6]  S. R. Rose,et al.  A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug , 2013, Clinical toxicology.

[7]  Simon D Brandt,et al.  Analyses of second-generation 'legal highs' in the UK: initial findings. , 2010, Drug testing and analysis.

[8]  E. Nunes,et al.  Treatment of Co-occurring Depression and Substance Dependence: Using Meta-analysis to Guide Clinical Recommendations. , 2008, Psychiatric annals.

[9]  H. Haughey,et al.  A Survey of Synthetic Cannabinoid Consumption by Current Cannabis Users , 2014, Substance abuse.

[10]  M. Barratt,et al.  Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. , 2013, Drug and alcohol dependence.

[11]  L. King,et al.  A brief history of 'new psychoactive substances'. , 2011, Drug testing and analysis.

[12]  Simon H. L. Thomas,et al.  Severe clinical toxicity associated with analytically confirmed recreational use of 25I–NBOMe: case series , 2013, Clinical toxicology.

[13]  Be Vang Dean,et al.  2C or Not 2C: Phenethylamine Designer Drug Review , 2013, Journal of Medical Toxicology.

[14]  N. Ferreirós,et al.  'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? , 2009, Journal of mass spectrometry : JMS.

[15]  A. Lewin,et al.  High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. , 2008, Bioorganic & medicinal chemistry.

[16]  Christopher Y Hopkins,et al.  A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. , 2013, The Journal of emergency medicine.

[17]  D J Nutt,et al.  A web-based survey on mephedrone. , 2011, Drug and alcohol dependence.

[18]  Gordon S. Smith,et al.  Sociodemographic Characteristics Associated with Substance Use Status in a Trauma Inpatient Population , 2007, Journal of addictive diseases.

[19]  R. Cook,et al.  College students and use of K2: an emerging drug of abuse in young persons , 2011, Substance abuse treatment, prevention, and policy.

[20]  J. Maxwell Psychoactive substances--some new, some old: a scan of the situation in the U.S. , 2014, Drug and alcohol dependence.

[21]  Rebecca Lynn Johnson,et al.  Current "legal highs". , 2013, The Journal of emergency medicine.

[22]  A. Kazory,et al.  Synthetic marijuana and acute kidney injury: an unforeseen association , 2013, Clinical kidney journal.

[23]  R. Bilici Synthetic cannabinoids , 2014, Northern clinics of Istanbul.

[24]  Patrick O'Malley,et al.  Monitoring the Future national survey results on drug use, 1975-2018: Overview, key findings on adolescent drug use , 2015 .

[25]  Kathryn Yung,et al.  Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces. , 2012, Military medicine.

[26]  J. Ramsey,et al.  Purchasing 'legal highs' on the Internet--is there consistency in what you get? , 2010, QJM : monthly journal of the Association of Physicians.

[27]  M. Barratt,et al.  The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample , 2014, Journal of psychopharmacology.

[28]  S. Dursun,et al.  Neurological complications of psychiatric drugs: clinical features and management , 2008, Human psychopharmacology.

[29]  Anneke Poortman,et al.  Instability of the ecstasy market and a new kid on the block: mephedrone , 2011, Journal of psychopharmacology.

[30]  R. Vandrey,et al.  A survey study to characterize use of Spice products (synthetic cannabinoids). , 2012, Drug and alcohol dependence.

[31]  Elizabeth L. Ogburn,et al.  Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. , 2007, Archives of general psychiatry.

[32]  Henry A Spiller,et al.  Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States , 2011, Clinical toxicology.

[33]  I. Vardakou,et al.  Drugs for youth via Internet and the example of mephedrone. , 2011, Toxicology letters.

[34]  M. Galanter,et al.  The American Psychiatric Publishing Textbook of Substance Abuse Treatment 4Ed , 2008 .

[35]  J. Kelly,et al.  Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. , 2011, Drug testing and analysis.

[36]  Lineke Zuurman,et al.  Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. , 2006, Journal of pharmaceutical sciences.

[37]  Erik W. Gunderson,et al.  Synthetic Cannabinoids: A New Frontier of Designer Drugs , 2013, Annals of Internal Medicine.

[38]  J. O'Riordan,et al.  A harmless high? , 2010, The Lancet.

[39]  V. Auwärter,et al.  Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. , 2013, Addiction.

[40]  J. Kornhuber,et al.  The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes , 2010, Schizophrenia Research.

[41]  Wayne Hall,et al.  Substance-Related Disorders , 2001 .

[42]  Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order. , 2011, Federal register.

[43]  C. Neighbors,et al.  Spicing up the military: Use and effects of synthetic cannabis in substance abusing army personnel. , 2014, Addictive behaviors.

[44]  A T McLellan,et al.  Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. , 2000, JAMA.

[45]  Simon L Hill,et al.  Clinical toxicology of newer recreational drugs , 2011, Clinical toxicology.

[46]  A. Obafemi,et al.  Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. , 2012, The American journal of emergency medicine.

[47]  G. Lloyd Textbook of Psychosomatic Medicine , 2006, British Journal of Psychiatry.

[48]  R. Spanagel,et al.  Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". , 2009, Deutsches Arzteblatt international.

[49]  C. R. Harris,et al.  Synthetic cannabinoid intoxication: a case series and review. , 2013, The Journal of emergency medicine.

[50]  A. Winstock,et al.  Mephedrone, new kid for the chop? , 2011, Addiction.

[51]  Kurt R. Lehner,et al.  Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive ‘Bath Salts’ Products , 2013, Neuropsychopharmacology.

[52]  D. Basu,et al.  Club drugs: review of the ‘rave’ with a note of concern for the Indian scenario , 2011, The Indian journal of medical research.

[53]  C. Kang,et al.  Three cases of “spice” exposure , 2011, Clinical toxicology.

[54]  R. Lindigkeit,et al.  Spice: a never ending story? , 2009, Forensic science international.

[55]  Y. Goda,et al.  Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. , 2010, Forensic science international.

[56]  W. Fratta,et al.  Beyond THC: The New Generation of Cannabinoid Designer Drugs , 2011, Front. Behav. Neurosci..

[57]  R. Rothman,et al.  The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue , 2012, Neuropsychopharmacology.

[58]  Morna L Gonsoulin,et al.  Pathological Findings in 2 Cases of Fatal 25I-NBOMe Toxicity , 2014, The American journal of forensic medicine and pathology.

[59]  P. Dargan,et al.  Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. , 2010, QJM : monthly journal of the Association of Physicians.

[60]  J. Maxwell,et al.  Profiles of Club Drug Users in Treatment , 2005, Substance use & misuse.

[61]  J. Poklis,et al.  Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. , 2014, Forensic science international.

[62]  I. Vardakou,et al.  Spice drugs as a new trend: mode of action, identification and legislation. , 2010, Toxicology letters.

[63]  P. Wax,et al.  The Toxicology Investigators Consortium Case Registry—The 2011 Experience , 2012, Journal of Medical Toxicology.

[64]  J. Ramsey,et al.  Mephedrone: use, subjective effects and health risks. , 2011, Addiction.

[65]  Barbara S. McCrady,et al.  Addictions: A Comprehensive Guidebook , 2013 .

[66]  M. Kirkpatrick,et al.  Substituted cathinone products: a new trend in "bath salts" and other designer stimulant drug use. , 2013, Journal of addiction medicine.

[67]  H. Haughey,et al.  "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. , 2012, The American journal on addictions.

[68]  P. Gahlinger,et al.  Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine. , 2004, American family physician.

[69]  T. Woo,et al.  "How high do they look?": identification and treatment of common ingestions in adolescents. , 2013, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.

[70]  L. Zamengo,et al.  Determination of illicit drugs in seized materials: role of sampling and analysis in estimation of measurement uncertainty. , 2011, Forensic science international.